phrykt

Artiva Biotherapeutics, Inc. (ARTV): who owns it and who trades it

As of Nov 16, 2026, ARTV insiders reported 23 open-market sales worth $2.9M and 22 purchases worth $109M in the last 12 months, with 6% of the sale value made under pre-set 10b5-1 plans. The largest seller was Fred Aslan (CEO), with $2.1M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Artiva Biotherapeutics

From the latest filings

Overall: about as much buying as selling. Famous investors mostly sold. Funds mostly bought. Insiders was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns ARTV

73 funds and institutions reported ARTV shares worth $395M at the end of Q2 2026, about 82% of the company. The largest holder is Ra Capital Management, L.P. with 36.3%.

Funds and institutions (13F) 82%Everyone else 18%

10 largest owners, by share of the company

Ra Capital Management, L.P.36.3%
Viking Global Investors LP5.3%
Blackstone Inc.4.9%
5AM Venture Management, LLC4.8%
Venrock Adviser, LLC4.1%
Franklin Resources Inc4.0%
Caligan Partners LP3.5%
Vanguard Capital Management LLC2.0%
Samsara Biocapital, LLC1.9%
Blue Owl Capital Holdings LP1.8%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Ra Capital Management, L.P.17.96M36.32%$174M+82%
Viking Global Investors LP2.60M5.27%$25.3MNew
Blackstone Inc.2.40M4.86%$23.3MNew
5AM Venture Management, LLC2.35M4.76%$22.8MNo change
Venrock Adviser, LLC2.04M4.13%$19.8M+27%
Franklin Resources Inc2.00M4.04%$19.4M+284%
Caligan Partners LP1.74M3.51%$16.8MNew
Vanguard Capital Management LLC981,8151.99%$9.5M+373%
Samsara Biocapital, LLC954,8611.93%$9.3MNew
Blue Owl Capital Holdings LP874,5421.77%$8.5MNew
Propel Bio Management, LLC696,4361.41%$6.8M+376%
BlackRock, Inc.694,7261.41%$6.7M+226%
Citadel Advisors LLC609,3761.23%$5.9M+3740%
Nantahala Capital Management, LLC600,0001.21%$5.8MNew
Silverarc Capital Management, LLC525,0001.06%$5.1MNew
Geode Capital Management, LLC353,8450.72%$3.4M+248%
Boothbay Fund Management, LLC314,3750.64%$3MNew
Revelation Capital Management, LLC299,3110.61%$2.9MNo change
Alyeska Investment Group, L.P.273,6150.55%$2.7M+174%
Acuta Capital Partners, LLC260,4160.53%$2.5MNew

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, ARTV insiders reported $109M of open-market purchases and $2.9M of sales. 6% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$109M
22 trades, 7 people
Sales, 12 months
$2.9M
23 trades, 5 people
Sales under a 10b5-1 plan
6%
Share of sale value
Latest trade
Nov 2, 2026
Filed Nov 3, 2026

Purchases and sales by month

$91.5M$91.5MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 2, 2026Fred AslanCEOSale62,178$4.18$260KForm 4
Nov 2, 2026Subhashis BanerjeeChief Medical OfficerSale1,110$4.18$4.6KForm 4
Nov 2, 2026Jennifer BushCOOSale8,439$4.18$35.3KForm 4
Nov 2, 2026Christopher HoranChief Tech Operations OfSale10,423$4.18$43.6KForm 4
Oct 6, 2026Fred AslanCEOSale plan23,463$7.20$169KForm 4
Oct 5, 2026Fred AslanCEOSale61,696$6.84$422KForm 4
Oct 5, 2026Subhashis BanerjeeChief Medical OfficerSale1,099$6.84$7.5KForm 4
Oct 5, 2026Jennifer BushCOOSale8,370$6.84$57.2KForm 4
Oct 5, 2026Christopher HoranChief Tech Operations OfSale10,340$6.84$70.7KForm 4
Sep 8, 2026Fred AslanCEOSale23,429$10.92$256KForm 4
Sep 3, 2026Christopher HoranChief Tech Operations OfSale10,366$11.16$116KForm 4
Sep 3, 2026Jennifer BushCOOSale8,391$11.16$93.6KForm 4
Sep 3, 2026Subhashis BanerjeeChief Medical OfficerSale1,100$11.16$12.3KForm 4
Sep 3, 2026Fred AslanCEOSale61,888$11.16$691KForm 4
Aug 27, 2026Subhashis BanerjeeChief Medical OfficerSale8,222$12.01$98.7KForm 4
Aug 18, 2026Subhashis BanerjeeChief Medical OfficerSale429$12.00$5.1KForm 4
Jul 31, 2026RA Capital Healthcare Fund LP +5DirectorPurchase24,944$9.93$248KForm 4
Jul 29, 2026RA Capital Healthcare Fund LP +5DirectorPurchase20,824$9.99$208KForm 4
Jul 24, 2026RA Capital Nexus Fund III, L.P. +5DirectorPurchase41,319$9.99$413KForm 4
Jul 23, 2026Peter Kolchinsky +5DirectorPurchase59,880$9.96$596KForm 4
Jul 22, 2026Peter Kolchinsky +5DirectorPurchase84,124$9.93$835KForm 4
Jul 21, 2026Peter Kolchinsky +5DirectorPurchase120,582$9.55$1.2MForm 4
Jul 17, 2026RA Capital Healthcare Fund LP +5DirectorPurchase7,882$8.95$70.5KForm 4
Jul 16, 2026RA Capital Healthcare Fund LP +5DirectorPurchase152,472$8.93$1.4MForm 4
Jul 13, 2026RA Capital Nexus Fund, L.P. +5DirectorPurchase6,522$8.94$58.3KForm 4
Jul 13, 2026Rajeev M. Shah +5DirectorPurchase6,552$8.94$58.6KForm 4
Jul 10, 2026Rajeev M. Shah +5DirectorPurchase15,102$8.97$135KForm 4
Jun 26, 2026Ra Capital Management, L.P. +5DirectorPurchase1,876$8.98$16.8KForm 4
Jun 25, 2026Ra Capital Management, L.P. +5DirectorPurchase31,000$8.88$275KForm 4
Jun 16, 2026Peter Kolchinsky +5DirectorPurchase124,893$8.89$1.1MForm 4
Jun 15, 2026Peter Kolchinsky +5DirectorPurchase15,414$8.99$139KForm 4
Jun 12, 2026Peter Kolchinsky +5DirectorPurchase391,019$8.57$3.4MForm 4
Jun 11, 2026RA Capital Nexus Fund, L.P. +5DirectorPurchase548,580$7.91$4.3MForm 4
Jun 10, 2026RA Capital Nexus Fund, L.P. +5DirectorPurchase103$7.00$721Form 4
Jun 9, 2026RA Capital Nexus Fund, L.P. +5DirectorPurchase479,039$6.91$3.3MForm 4
May 19, 2026Heather RaymonVice presidentSale3,095$9.01$27.9KForm 4
May 19, 2026Christopher HoranChief Tech Operations OfSale7,002$9.01$63.1KForm 4
May 19, 2026Jennifer BushCOOSale8,790$9.01$79.2KForm 4
May 19, 2026Subhashis BanerjeeChief Medical OfficerSale7,037$9.01$63.4KForm 4
May 19, 2026Fred AslanCEOSale27,116$9.01$244KForm 4
May 11, 2026GC Corp. +110% ownerPurchase1.09M$11.52$12.5MForm 4
May 11, 2026GC Corp. +110% ownerPurchase347,222$11.52$4MForm 4
May 11, 2026RA Capital Nexus Fund III, L.P. +5DirectorPurchase6.51M$11.52$75MForm 4
Dec 15, 2025Fred AslanCEOSale3,187$6.00$19.1KForm 4
Nov 17, 2025Fred AslanCEOSale6,375$3.38$21.5KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
RA Capital Nexus Fund III, L.P.Director$75.4M–Jul 24, 2026
GC Corp.10% owner$16.5M–May 11, 2026
RA Capital Nexus Fund, L.P.Director$7.7M–Jul 13, 2026
Peter KolchinskyDirector, 10% owner$7.2M–Jul 23, 2026
Fred AslanPresident and CEO, Director–$2.1MNov 2, 2026
RA Capital Healthcare Fund LPDirector, 10% owner$1.9M–Jul 31, 2026
Christopher HoranChief Tech Operations Officer–$293KNov 2, 2026
Ra Capital Management, L.P.Director, 10% owner$292K–Jun 26, 2026
Jennifer BushCOO, CLO, Compliance Officer–$265KNov 2, 2026
Rajeev M. ShahDirector, 10% owner$194K–Jul 13, 2026
Subhashis BanerjeeChief Medical Officer–$192KNov 2, 2026
Heather RaymonSVP, Research and Development–$27.9KMay 19, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ARTV short interest

Moderate short interest. 6.0% of ARTV shares are sold short: about 1 share in 17. Over the last 12 reports the number of shares short went up 515%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 2.95M ARTV shares were sold short, 6.0% of the shares outstanding, up 7.9% from the report before. At the average daily volume of 1.64M shares, buying them all back would take about 1.8 trading days (days to cover).

Shares short, % of all shares

5.98%May 15Oct 307.73%

Days to cover

1.8May 15Oct 307.6

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20262.95M5.98%+8%1.64M1.8
Oct 15, 20262.74M5.60%+19%456,1566.0
Sep 30, 20262.30M4.70%+11%625,9443.7
Sep 15, 20262.07M4.22%+12%310,6876.7
Aug 31, 20261.84M3.76%-12%273,7386.7
Aug 14, 20262.10M4.29%+9%345,5146.1
Jul 31, 20261.92M3.93%+11%374,4745.1
Jul 15, 20261.72M6.98%+29%457,8953.8
Jun 30, 20261.34M5.42%+24%734,6331.8
Jun 15, 20261.08M4.37%+5%660,7431.6
May 29, 20261.03M4.15%+113%518,6682.0
May 15, 2026480,5791.94%+109%777,7691.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Artiva Biotherapeutics company events

Artiva Biotherapeutics filed 12 reports on Form 8-K in the last 12 months, 7 of them about an important change (leadership, job cuts). The latest was on Nov 9, 2026.

  1. Nov 9, 2026Job cutsAmended an earlier report. Announced job cuts or other exit costs. Filing
  2. Oct 27, 2026Job cutsAnnounced job cuts or other exit costs. Filing
  3. Sep 11, 2026LeadershipThe Company held its 2026 Annual Meeting of Stockholders. Filing
  4. Aug 6, 2026ResultsReleased financial results. Filing
  5. Jul 22, 2026AnnouncementArtiva Biotherapeutics, Inc. today announced that the expected date for the Company’s 2026 annual meeting of stockholders is September 8, 2026, which is more than 70 days after the one-year anniversary of the Company’s 2025 annual meeting of stockholders. Filing
  6. May 19, 2026LeadershipDiego Miralles, M.D. resigned as a member of the Board of Directors of Artiva Biotherapeutics, Inc., effective May 18, 2026, in connection with his appointment as President and Head of Research and Development of the Company as described below. Filing
  7. May 8, 2026AnnouncementArtiva Biotherapeutics, Inc. entered into an underwriting agreement with Jefferies LLC, TD Securities (USA) LLC and Cantor Fitzgerald & Co., as representatives of the several underwriters listed therein, to issue and sell 23,871,526 shares of the Company’s common stock, par value $0.0001 per share… Filing
  8. May 8, 2026AnnouncementThe Company delivered written notice to Leerink Partners LLC that the Company has suspended and is not offering any shares of its common stock pursuant to the prospectus filed with the SEC on August 6, 2025, relating to the Sales Agreement, dated August 6, 2025, by and between the Company and… Filing
  9. Mar 10, 2026ResultsReleased financial results. Filing
  10. Feb 24, 2026LeadershipArtiva Biotherapeutics, Inc. announced that its Board of Directors appointed Thad Huston as the Company's Chief Financial Officer. Filing
  11. Feb 19, 2026LeadershipThe Board of Directors of Artiva Biotherapeutics, Inc., upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Elaine Sorg as a Class I director of the Company, with a term of office expiring at the Company’s 2028 annual meeting of stockholders. Filing
  12. Dec 12, 2025LeadershipOn December 10-11, 2025, Artiva Biotherapeutics, Inc. (the Company) entered into Option for RSU Exchange Agreements (the Option for RSU Exchange Agreements) with a limited number of employees, including Fred Aslan, the Company’s President and Chief Executive Officer, and Jennifer Bush, the… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Artiva Biotherapeutics financials

Famous investors that hold ARTV

4 of the 50 well-known investors we track reported holding ARTV in their latest 13F filing. The largest position is Andreas Halvorsen's, worth $18.5M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Andreas Halvorsen · Viking Global InvestorsQ3 20262.60M$18.5M0.1%No change
Jim Simons · Renaissance TechnologiesQ3 202674,078$527K0.0%-51%
Israel Englander · Millennium ManagementQ3 202644,461$317K0.0%New
Ken Griffin · Citadel AdvisorsQ3 202616,397$117K0.0%-97%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Artiva Biotherapeutics, Inc. (ARTV) stock

Who owns the most ARTV stock?

The largest reported owner of Artiva Biotherapeutics, Inc. (ARTV) is Ra Capital Management, L.P., with 36.3% of the company. In total, 73 funds and institutions reported holding ARTV at the end of Q2 2026, together about 82% of the shares. See the largest owners.

Are ARTV insiders buying or selling?

In the last 12 months, ARTV insiders reported 22 open-market purchases worth $109M and 23 sales worth $2.9M. The latest trade was on Nov 2, 2026. See every trade.

What is the short interest in ARTV?

As of Oct 30, 2026, 2.95M ARTV shares were sold short, 6.0% of the shares outstanding, up 7.9% from the report before. At the average daily volume of 1.64M shares, buying them all back would take about 1.8 trading days (days to cover). See the history.

Which famous investors hold ARTV?

4 of the 50 well-known investors we track reported ARTV in their latest 13F filing, including Andreas Halvorsen, Jim Simons, Israel Englander. The largest position is worth $18.5M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.